Researchers at the Kimmel Cancer Center at Jefferson have developed potentially game-changing diagnostic and prognostic genetic tests shown to better predict prostate cancer survival outcomes and distinguish clinically-relevant cancers.
Johns Hopkins researchers report concrete steps in the use of human stem cells to test how diseased cells respond to drugs. Their success highlights a pathway toward faster, cheaper drug development for some genetic illnesses, as well as the ability to pre-test a therapy’s safety and effectiveness on cultured clones of a patient’s own cells.
Ge Wang, director of Virginia Tech’s Center for Biomedical Imaging, has a history of “firsts” in the imaging world, including the first paper on spiral multi-slice/cone-beam CT in 1991, on bioluminescence tomography in 2004, and on interior tomography in 2007. In a recent paper that appeared in the refereed journal PLoS One, Wang speaks about new combinations of medical imaging technologies that hold promise for improved early disease screening, cancer staging, therapeutic assessment, and other aspects of personalized medicine. The integration of multiple major tomographic scanners into a single framework is a new way of thinking in the biomedical imaging world and is evolving into a grand fusion of many imaging modalities known as omni-tomography.
An ongoing program is developing new tools for assessing health care quality from the most important viewpoint—that of the patient receiving care, according to a special supplement to Medical Care. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
UC San Diego Moores Cancer Center launched a bold plan today, aimed at personalizing cancer treatment. The “My Answer to Cancer” team of oncologists, bioinformaticians, pathologists and geneticists pledges to “sequence” or analyze the DNA of large numbers of patients with cancer in order to match each patient to the best available drug for his or her particular tumor.
Advancements in sequencing and diagnostics technology are the underlying elements driving the genomic revolution. With the free-falling cost of sequencing, richer reference data and improved interpretation methods, the use of personal genomics is beginning to take greater root in clinical practice.
People with a family history of certain diseases, including heart disease and diabetes, often underestimate their risk for developing them, even after completing a risk assessment and receiving personalized prevention messages, finds a new study in the American Journal of Preventive Medicine.
A new tool to observe cell behavior has revealed surprising clues about how cancer cells respond to therapy, and may offer a way to further refine personalized cancer treatments. The approach, developed by investigators at Vanderbilt-Ingram Cancer Center, shows that erlotinib — a targeted therapy that acts on a growth factor receptor mutated in some lung, brain and other cancers — doesn’t simply kill tumor cells as was previously assumed. The drug also causes some tumor cells to go into a non-dividing (quiescent) state or to slow down their rate of division.
As a key step toward providing patients with treatments based on their own DNA profiles, the University of Michigan and the International Genomics Consortium (IGC) have launched a new joint venture that will help usher in an age of personalized medicine.
Personalized medicine has promised to radically change the way we look at health and disease. Talk of tailored drug therapies and early detection of cancer has captured the attention of scientists and lay people alike. So when will patients start to reap the benefits of this medical revolution? The transition to personalized medicine won’t be seamless or swift, says Lee Gutkind, who co-authored "An Immense New Power to Heal: The Promise of Personalized Medicine" (In Fact Books, May 2012) with novelist and science writer Pagan Kennedy.
Decoding the DNA of patients with advanced breast cancer has allowed scientists at Washington University School of Medicine in St. Louis to identify distinct cancer “signatures” that could help predict which women are most likely to benefit from estrogen-lowering therapy, while sparing others from unnecessary treatment.
Technion researchers have identified a biomarker shown to predict Parkinson's disease with high accuracy. It could ID at-risk individuals before symptoms develop, when prevention treatment efforts might have the greatest impact to slow disease progression.
Analyzing medical records from thousands of patients, statisticians have devised a statistical model for predicting what other medical problems a patient might encounter.
Researchers at NYU School of Medicine have, for the first time, identified a single gene that simultaneously controls inflammation, accelerated aging and cancer.
The Association for Molecular Pathology (AMP) today announced that it is close to finalizing a framework proposal for CPT coding of Next Generation Sequencing (NGS) assays.
Researchers from Memorial Sloan-Kettering Cancer Center have begun testing for three new genetic targets and found that together they occur in approximately 50 percent of patients with squamous cell carcinomas of the lung, which affects 40,000 Americans each year. Initial findings of the research will be presented on June 4 at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.
Mayo Clinic has created a comprehensive mobile health application; combining a custom mobile experience with unparalleled expertise and access. Empowering patients with information at their fingertips, this app sets a new standard for health care apps.
With recent advancements in technology and biomedical informatics, a more personalized approach to prescribing cancer treatment and developing these therapies is preferred over “one-size-fits-all” methods. The Cancer Institute of New Jersey has been on the cutting-edge of this movement and is now launching a more concrete effort that is poised to change the way that molecular and genetic information is being used to diagnose and treat cancer – an initiative known as “precision medicine” – also known to many as “personalized medicine.”
Patients see potential benefits from direct-to-consumer genetic testing, but are also concerned about how test results will be used, and generally are unwilling to pay more than $10 or $20 for them.
Through a groundbreaking new gene sequencing technology, researchers have demonstrated that the gene FLT3 is a valid therapeutic target in Acute Myeloid Leukemia, AML, one of the most common types of leukemia. The technique, developed by Pacific Biosciences, allows for the rapid and comprehensive detection of gene mutations in patients with AML. The findings, published online April 15 in Nature, are a result of collaboration among scientists at the University of California, San Francisco, Pacific Biosciences and Mount Sinai School of Medicine. The discovery may help lead to the development of new drugs to treat AML.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right